Objective To study the long-term effect of neoadjuvant chemotherapy on advanced breast cancer.
Methods The CAF neoadjuvant chemotherapy 〔CTX 500 mg/m2（1st day, 8th day), 5-FU 500 mg/m2（1st day, 8th day), and ADM 30 mg/m2 (1st day) every 3 weeks〕 was carried out in 31 breast cancer patients (stageⅢ,Ⅳ) for 2 cycles before operation, compared with 30 patients (stage Ⅲa) whose therapies were never done and operations could be feasible.
Results The overall response rate was 87.1%(27/31). The stages of 19 patients among 31 (61.3%) declined (6 patients to stage Ⅲa, 8 to stageⅡb, 4 to stageⅡa, 1 to stage 0, 1 to complete response and none to pathological complete response). The diseasefree survival time of the patients was 56.3 months which was obviously longer than that of the patients without neoadjuvant chemotherapy (43.5 months, P＜0.05). The 5-year diseasefree survival rate of the patients with neoadjuvant chemotherapy was 38.7% which was a little higher than that (33.3%) of the patients without the chemotherapy, and the two groups had no significant difference.
Conclusion The neoadjuvant chemotherapy can reduce the stages of patients with advanced breast cancer, obviously prolong the diseasefree survival time of patients, and reduce or delay recurrence or metastasis.
Citation：
LI Hui,NIAO Chuangui,HE Xiaomei. Clinical Analysis on Neoadjuvant Chemotherapy of Advanced Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2004, 11(1): 20-21. doi:
Copy
Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. |
Hayward JL, Carbone PP, Heusen JC, et al. Assessment of response to therapy in advanced breast cancer [J]. Br J Cancer, 1977; 35(3)∶292.
|
| 2. |
Wang HC, Lo SS. Future prospects of neoadjuvant chemotherapy in treatment of primary breast cancer [Ｊ]. Semin Surg Oncol, 1996; 12(1)∶59.
|
| 3. |
Gradishar WJ. Recently initiated studies: neoadjuvant treatments in the next century [Ｊ]. Semin Oncol, 1999; 26(1)∶26.
|
| 4. |
Sapunar F, Smith IE. Neoadjuvant chemotherapy for breast cancer [Ｊ]. Ann Med, 2000; 32(1)∶43.
|
| 5. |
Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group [Ｊ]. J Clin Oncol, 1996; 14(9)∶2552.
|
| 6. |
Bonadonna G, Valagussa P, Zucali R, et al. Primary chemotherapy in surgically resectable breast cancer [Ｊ]. CA Cancer J Clin, 1995; 45(4)∶227.
|
- 1. Hayward JL, Carbone PP, Heusen JC, et al. Assessment of response to therapy in advanced breast cancer [J]. Br J Cancer, 1977; 35(3)∶292.
- 2. Wang HC, Lo SS. Future prospects of neoadjuvant chemotherapy in treatment of primary breast cancer [Ｊ]. Semin Surg Oncol, 1996; 12(1)∶59.
- 3. Gradishar WJ. Recently initiated studies: neoadjuvant treatments in the next century [Ｊ]. Semin Oncol, 1999; 26(1)∶26.
- 4. Sapunar F, Smith IE. Neoadjuvant chemotherapy for breast cancer [Ｊ]. Ann Med, 2000; 32(1)∶43.
- 5. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group [Ｊ]. J Clin Oncol, 1996; 14(9)∶2552.
- 6. Bonadonna G, Valagussa P, Zucali R, et al. Primary chemotherapy in surgically resectable breast cancer [Ｊ]. CA Cancer J Clin, 1995; 45(4)∶227.
